Gilead Sciences (GILD) : Capwealth Advisors scooped up 3,066 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 113,101 shares of Gilead Sciences which is valued at $9,058,259.Gilead Sciences makes up approximately 2.16% of Capwealth Advisors’s portfolio.
Other Hedge Funds, Including , Diam Ltd. reduced its stake in GILD by selling 20,299 shares or 4.91% in the most recent quarter. The Hedge Fund company now holds 393,174 shares of GILD which is valued at $31,489,306. Gilead Sciences makes up approx 0.45% of Diam Ltd.’s portfolio.Sumitomo Life Insurance Co reduced its stake in GILD by selling 19,443 shares or 30.78% in the most recent quarter. The Hedge Fund company now holds 43,731 shares of GILD which is valued at $3,801,536. Gilead Sciences makes up approx 0.50% of Sumitomo Life Insurance Co’s portfolio.Capital Analysts reduced its stake in GILD by selling 329 shares or 2.17% in the most recent quarter. The Hedge Fund company now holds 14,814 shares of GILD which is valued at $1,287,781. Gilead Sciences makes up approx 0.25% of Capital Analysts’s portfolio.Braver Wealth Management reduced its stake in GILD by selling 27 shares or 0.07% in the most recent quarter. The Hedge Fund company now holds 39,932 shares of GILD which is valued at $3,424,169. Gilead Sciences makes up approx 0.57% of Braver Wealth Management’s portfolio.Newman Dignan Sheerar reduced its stake in GILD by selling 1,756 shares or 24.97% in the most recent quarter. The Hedge Fund company now holds 5,277 shares of GILD which is valued at $456,724. Gilead Sciences makes up approx 0.29% of Newman Dignan Sheerar’s portfolio.
Gilead Sciences closed down -0.67 points or -0.83% at $79.74 with 95,11,596 shares getting traded on Monday. Post opening the session at $80.46, the shares hit an intraday low of $79.01 and an intraday high of $80.79 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.